Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.7%: Chuikyo
May 19, 2017
- MHLW Discussing Restrictions on Prescriptions of Codeine-Containing Medicines to Children
May 19, 2017
- JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May 19, 2017
- JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May 19, 2017
- Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
- Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
- FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May 18, 2017
- MHLW Advisory Panel to Review Eli Lilly’s JAK Inhibitor Baricitinib on May 30
May 18, 2017
- (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May 17, 2017
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
- 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
- Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
- Japan, South Korea Set Up Working Groups to Collaborate on Harmonization
May 16, 2017
- Procedures for Providing Unapproved Drugs to Developing Countries in Emergencies Could Become Finalized in June
May 15, 2017
- Transition Period of “at Least 1 Year” Needed for New Package Insert Format: MHLW
May 11, 2017
- Marketing Strategies for Participating Hospitals to Be Important for Drug Makers to Effectively Use MID-NET: PMDA Official
May 11, 2017
- LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
- Japan, US Ink Memorandum of Cooperation on Health
May 9, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…